Axial Spondyloarthritis
📧 Sign up to get email alerts when something new happens for Axial Spondyloarthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) for multiple indications including psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile a…
-
CLINICAL_TRIALS trial_result · 2026-08-14Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial evaluating long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis including ankylosing …
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial update evaluating long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis including anky…
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-01EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
European Medicines Agency authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including various form…
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-09EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
EU authorization of Rinvoq (upadacitinib) by AbbVie Deutschland for multiple inflammatory indications including rheumatoid arthritis, psoria…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial evaluating the long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis, including ankylo…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults [Phase 1]
A Phase 1 clinical trial is evaluating the safety and pharmacokinetics of bimekizumab given in different administration methods in adults wi…
-
EMA approval · 2026-04-23EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) from Eli Lilly for psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthri…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of SPY072 in Rheumatic Disease [Phase 2]
This clinical trials update outlines a Phase 2 study of SPY072 for rheumatoid arthritis and psoriatic arthritis, with ongoing recruitment an…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA. [Phase 2, Phase 3]
The trial evaluates the diagnostic performance of the radiotracer [18F]-AlF-FAPI-74 PET/CT for inflammatory disorders and compares it with F…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) [Phase 1, Phase 2]
Grey Wolf Therapeutics is recruiting for EAST-1, a Phase 1/2 trial of an ERAP inhibitor for axial spondyloarthritis.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases [Phase 4]
Phase 4 clinical trial assessing safety and immunogenicity of the live attenuated tetravalent Butantan-Dengue vaccine in autoimmune rheumati…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study
A real-world cohort study in China is investigating disease progression in axial spondyloarthritis, including ankylosing spondylitis, and is…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis [Phase 4]
This Phase 4 clinical trial registry entry describes evaluating upadacitinib's impact on spondyloarthritis outcomes in patients with active …
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) [Phase 1]
A Phase 1 study is evaluating the concentration of Bimzelx (bimekizumab) in mature breast milk in mothers receiving treatment, and is curren…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib
The clinical study evaluating changes in early and sustained pain control in adults with axial spondyloarthritis treated with Upadacitinib h…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis [NA]
A clinical trial in Strasbourg is evaluating fatigue and skeletal muscle impact in patients with severe axial spondyloarthritis; the study i…
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Multimodal Pulmonary Rehabilitation in Radiographic Axial Spondyloarthritis [NA]
This clinical trial update describes a multimodal pulmonary rehabilitation study for radiographic axial spondyloarthritis conducted by Balik…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Walking Football for Axial Spondyloarthritis [NA]
This clinical trial update indicates that Walking Football for Axial Spondyloarthritis is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis [Phase 4]
A Phase 4 clinical trial is evaluating whether upadacitinib affects the frequency of acute recurrent anterior uveitis in patients with axial…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica
This clinical trial update describes a study funded by Hôpital NOVO investigating the association between sacroiliitis/axial spondyloarthrit…